

EPA133Ra61 100µg Eukaryotic Tumor Necrosis Factor Alpha (TNFa) Organism Species: *Rattus norvegicus (Rat) Instruction manual*

FOR RESEARCH USE ONLY

NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

12th Edition (Revised in Aug, 2016)

Cond-Clone Corp.

[PROPERTIES]

Source: Eukaryotic expression Host: CHO Cell Residues: Leu80~Leu235 Tags: N-terminal His Tag and C-terminal Fc Region of Human IgG1 Subcellular Location: Secreted **Purity:** > 97% Traits: Freeze-dried powder Buffer formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 0.01% SKL, 5% Trehalose. Original Concentration: 200µg/mL Applications: Positive Control; Immunogen; SDS-PAGE; WB. (May be suitable for use in other assays to be determined by the end user.) Predicted isoelectric point: 4.7 Predicted Molecular Mass: 47.8kDa Accurate Molecular Mass: 25&18kDa as determined by SDS-PAGE reducing conditions. Phenomenon explanation: The possible reasons that the actual band size differs from the predicted are as follows: 1.Splice variants: Alternative splicing may create different sized proteins from the same gene. 2. Relative charge: The composition of amino acids may affects the charge of the protein. 3. Post-translational modification: Phosphorylation, glycosylation, methylation etc. 4. Post-translation cleavage: Many proteins are synthesized as pro-proteins, and then cleaved to give the active form. 5. Polymerization of the target protein: Dimerization, multimerization etc. [USAGE]

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[STORAGE AND STABILITY]



Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Stability Test: The thermal stability is described by the loss rate. The loss rate was determined

by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no

obvious degradation and precipitation were observed. The loss rate is less than 5% within the

expiration date under appropriate storage condition.

[SEQUENCE]

L RSSSQNSSDK PVAHVVANHQ AEEQLEWLSQ RANALLANGM DLKDNQLVVP ADGLYLIYSQ VLFKGQGCPD YVLLTHTVSR FAISYQEKVS LLSAIKSPCP KDTPEGAELK PWYEPMYLGG VFQLEKGDLL SAEVNLPKYL DITESGQVYF GVIAL



ERGETERTUT MATUSGERENGUERGENETAGUERGENETGEGENETGEGEREGEGEGEGEGEGENEGUT.GEGENETGETERGETEGETEGENETGEGETEGET.CENORGETEGETEGENETGEGETEGENETGEGETEGENETGEGETEGENETGEGETEGENETGETEGENETGETEGENET I R S S S Q N S S D K P V A H V V A N H Q A E E Q L E V I S Q R A N A L L A N G N D L K D N Q L V V P A D G L V I I Y S Q V I F K G Q G C P D V V I I T H T V S R F .




Figure . Gene Sequencing (extract)




Figure. SDS-PAGE

[<u>IMPORTANT NOTE</u>]



The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.